203 related articles for article (PubMed ID: 37850692)
21. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
22. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
[TBL] [Abstract][Full Text] [Related]
23. A novel prognostic related lncRNA signature associated with amino acid metabolism in glioma.
Lei Q; Yuan B; Liu K; Peng L; Xia Z
Front Immunol; 2023; 14():1014378. PubMed ID: 37114036
[TBL] [Abstract][Full Text] [Related]
24. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
25. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
26. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
Lei H; Xiang T; Zhu H; Hu X
Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
[TBL] [Abstract][Full Text] [Related]
27. LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma.
Zhu X; Chen D; Sun Y; Yang S; Wang W; Liu B; Gao P; Li X; Wu L; Ma S; Lin W; Ma J; Yan D
BMC Cancer; 2023 Feb; 23(1):120. PubMed ID: 36747161
[TBL] [Abstract][Full Text] [Related]
28. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
29. Integrative Analysis of Inflammatory Response-Related Gene for Predicting Prognosis and Immunotherapy in Glioma.
Zhao Z; Zheng B; Zheng J; Zhang Y; Jiang C; Nie C; Jiang X; Yao D; Zhao H
J Mol Neurosci; 2023 Aug; 73(7-8):608-627. PubMed ID: 37488455
[TBL] [Abstract][Full Text] [Related]
30. Profiling pro-neural to mesenchymal transition identifies a lncRNA signature in glioma.
Liang Q; Guan G; Li X; Wei C; Wu J; Cheng P; Wu A; Cheng W
J Transl Med; 2020 Oct; 18(1):378. PubMed ID: 33028341
[TBL] [Abstract][Full Text] [Related]
31. A Novel Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response of Glioma.
Wu Z; Liu M; Fu J; Li J; Qin L; Wu L; Chen H; Yan X; Liu Q; Zheng J
Biomed Res Int; 2022; 2022():3742447. PubMed ID: 35757472
[TBL] [Abstract][Full Text] [Related]
32. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
[TBL] [Abstract][Full Text] [Related]
33. Identification of Prognostic Signature of Necroptosis-Related lncRNAs and Molecular Subtypes in Glioma.
Zhang G; Chen R; Zhu L; Ma H; Tang H; Shang C; Wang J; Zhang D; Li Q; Liu J
Comput Math Methods Med; 2022; 2022():3440586. PubMed ID: 36110575
[TBL] [Abstract][Full Text] [Related]
34. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
35. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
36. PD-L1-related IncRNAs are associated with malignant characteristics and immune microenvironment in glioma.
Xia Z; Tu R; Liu F; Zhang H; Dai Z; Wang Z; Luo P; He S; Xiao G; Feng J; Cheng Q
Aging (Albany NY); 2023 Oct; 15(19):10785-10810. PubMed ID: 37837543
[TBL] [Abstract][Full Text] [Related]
37. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
38. Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy.
Cheng Q; Duan W; He S; Li C; Cao H; Liu K; Ye W; Yuan B; Xia Z
Front Cell Dev Biol; 2021; 9():686909. PubMed ID: 34336837
[TBL] [Abstract][Full Text] [Related]
39. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
40. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]